Literature DB >> 10648647

Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites.

J P Lees-Miller1, Y Duan, G Q Teng, H J Duff.   

Abstract

This study reports that the affinity of HERG1 A for dofetilide is decreased from 0.125 +/- 0.003 microM for wild-type (WT) channels to 15 +/- 3 microM for F656V, a mutation in the COOH-terminal half of the S6. Similarly, the IC(50) for quinidine was increased from 8 +/- 4 microM for WT to 219 +/- 65 microM for the F656V mutation, whereas affinity for external tetraethylammonium was similar for WT (51 +/- 10 mM) and F656V (36 +/- 10 mM, NS). Kinetics of onset of inactivation of F656V was similar to WT but kinetics of deactivation, activation, and recovery from inactivation differed from WT. However, mutations in nearby amino acids in the S6 more strikingly altered deactivation, activation, and recovery from inactivation but had little effect on affinity for dofetilide. To assess the effects of disruption of inactivation, the S631A mutation was made. The S631A mutation altered the IC(50) for dofetilide to 20 +/- 3 microM, but the IC(50) for quinidine was unchanged at 8 +/- 4 microM for WT and 10 +/- 1 microM for S631A. To address whether the F656V mutation alters the IC(50) for dofetilide in a channel that does not inactivate, the double mutation S631A/F656V was made. The IC(50) for dofetilide of the double mutation was 32 +/- 3 microM, which is not substantially different than that of S631A. These data support the notion that allosteric changes occurring during the process of inactivation are necessary for high-affinity dofetilide binding. In conclusion, the Phe-656 residue of HERG is a molecular determinant of high-affinity dofetilide binding.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10648647

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  71 in total

Review 1.  Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine.

Authors:  John S Mitcheson
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

2.  Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels.

Authors:  Jun Chen; Guiscard Seebohm; Michael C Sanguinetti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-03       Impact factor: 11.205

Review 3.  Revealing the structural basis of action of hERG potassium channel activators and blockers.

Authors:  Matthew Perry; Michael Sanguinetti; John Mitcheson
Journal:  J Physiol       Date:  2010-07-19       Impact factor: 5.182

Review 4.  hERG quality control and the long QT syndrome.

Authors:  Brian Foo; Brittany Williamson; Jason C Young; Gergely Lukacs; Alvin Shrier
Journal:  J Physiol       Date:  2016-02-09       Impact factor: 5.182

5.  The Link between Inactivation and High-Affinity Block of hERG1 Channels.

Authors:  Wei Wu; Alison Gardner; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2015-04-08       Impact factor: 4.436

6.  The evolutionarily conserved residue A653 plays a key role in HERG channel closing.

Authors:  Svetlana Z Stepanovic; Franck Potet; Christina I Petersen; Jarrod A Smith; Jens Meiler; Jeffrey R Balser; Sabina Kupershmidt
Journal:  J Physiol       Date:  2009-04-30       Impact factor: 5.182

7.  Interactions of H562 in the S5 helix with T618 and S621 in the pore helix are important determinants of hERG1 potassium channel structure and function.

Authors:  James P Lees-Miller; Julia O Subbotina; Jiqing Guo; Vladimir Yarov-Yarovoy; Sergei Y Noskov; Henry J Duff
Journal:  Biophys J       Date:  2009-05-06       Impact factor: 4.033

8.  Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs.

Authors:  M J McPate; R S Duncan; J C Hancox; H J Witchel
Journal:  Br J Pharmacol       Date:  2008-08-25       Impact factor: 8.739

9.  hERG gating microdomains defined by S6 mutagenesis and molecular modeling.

Authors:  Sarah L Wynia-Smith; Anne Lynn Gillian-Daniel; Kenneth A Satyshur; Gail A Robertson
Journal:  J Gen Physiol       Date:  2008-11       Impact factor: 4.086

10.  Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.

Authors:  James T Milnes; Olivia Crociani; Annarosa Arcangeli; Jules C Hancox; Harry J Witchel
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.